Damora Therapeutics, Inc. Common Stock’s (DMRA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report published on Tuesday,Benzinga reports. They currently have a $45.00 price objective on the stock.

A number of other equities analysts have also weighed in on DMRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective on the stock. TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They set a “buy” rating on the stock. Royal Bank Of Canada started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Down 2.7%

NASDAQ DMRA opened at $29.17 on Tuesday. The stock’s 50-day moving average price is $25.47 and its 200-day moving average price is $25.75. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.45 and a 52 week high of $38.33. The company has a market capitalization of $1.80 billion, a P/E ratio of -5.23 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DMRA. Ikarian Capital LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $6,574,000. Jain Global LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $2,774,000. Remedium Capital Partners LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $2,772,000. Boothbay Fund Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,204,000. Finally, Connective Capital Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter valued at $100,000. 14.20% of the stock is owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.